NTRA Natera, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:46
Sep 03
Sep 03
Promising precision medicine; wait for pullback.
Natera has transformed from prenatal testing into a precision medicine platform with strong cancer-test volume growth, transplant tests, raised revenue guidance, and a large Druckenmiller position. The stock has run up and is not cheap on sales, so Cramer would wait for a pullback before buying.
MED
03:46
Aug 12
Aug 12
Guggenheim raises its price target on Natera to 360 dollars from 290 dollars.
04:14
Aug 07
Aug 07
TD Cowen raises Natera price target to 340 from 325 while maintaining a positive outlook.
TD Cowen raises Natera price target to 340 from 325 while maintaining a positive outlook on the stock.
08:30
Jul 23
Jul 23
Quest's Haystack MRD test received New York State approval; management noted only one other company has a tumor-informed MRD test cleared by NY State, implying a competitive edge. — Positions Quest as a leader in the MRD space alongside Natera (Signatera), potentially pressuring Guardant's Reveal and other naïve tests.
MED
08:30
Jul 19
Jul 19
Buy Guardant Health and Natera on biotech rotation.
Retail investors are rotating out of crowded tech positions into biotech and healthcare. Guardant Health (liquid biopsy, early cancer detection) and Natera (genetic testing, recurrence monitoring) are leading liquid-biopsy companies that rank high among retail purchases. This rotation into defensive biotech leaders gives them added demand and supports a positive outlook.
MED
04:27
Jun 12
Jun 12
RBC restarted coverage on Natera Inc with an Outperform rating and a price target of 275.
RBC restarted coverage on Natera Inc with an Outperform rating and a price target of 275 dollars.
15:45
May 16
May 16
Reports David Tepper (Druck) Q1 2026 13F additions; speaker provides no personal thesis.
HIGH
About NTRA Analyst Coverage
Buzzberg tracks NTRA (Natera, Inc. Common Stock) across 5 sources. 1 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (14%). 7 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Jim Cramer, FirstSquawk, Jim Davis.